Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024
Company to report data from all three ongoing clinical programs in 2024
— AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H —
Related news for (RNA)
- TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
- Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
- 24/7 Market News Snapshot 08 October, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)
- Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales
- Today’s Top Performers: MoBot’s Market Review 10/08/25 09:00 AM
